Caulfield MDG, Brar R, Sutherland C, Nolan S Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach BMJ Case Rep, 2020. PubMed

Lavalley J, Kastor S, Tourangeau M, Western Aboriginal Harm Reduction Society, Goodman A, Kerr T You just have to have other models, our DNA is different: the experiences of Indigenous people who use illicit drugs and/or alcohol accessing substance use treatment Harm Reduct J, 2020. PubMed

Kennedy MC, Hayashi K, Milloy MJ, Boyd J, Wood E, Kerr T Supervised injection facility use and exposure to violence among a cohort of people who inject drugs: a gender-based analysis Int J Drug Policy, 2020. PubMed

Socías ME, Wood E, Dong H, Brar R, Bach P, Murphy SM, Fairbairn N Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): protocol for a non-inferiority randomized clinical trial Contemp Clin Trials, 2020. PubMed

Dahlby L, Kerr T PTSD and opioid use: implications for intervention and policy Subst Abuse Treat Prev Policy, 2020. PubMed

Bach P, Ti L Hepatitis C and stimulant use disorder: challenges and opportunities Clin Infect Dis, 2020. PubMed

Bach P, Garrod E, Robinson K, Fairbairn N An acute care contingency management program for the treatment of stimulant use disorder: a case report J Addict Med, 2020. PubMed

Mackay L, Ickowicz S, Hayashi K, Abrahams R Rooming-in and loss of child custody: key factors in maternal overdose risk Addiction, 2020. PubMed

Ickowicz S, Brar R, Nolan S Case study: naltrexone for the treatment of nitrous oxide use J Addict Med, 2020. PubMed

Ickowicz S, Grant C, Nosova E, Boyd J, Brar R, Milloy MJ, Hayashi K, Nolan S Factors associated with the use of supervised consumption facilities among women who inject drugs in a Canadian setting J Addict Med, 2020. PubMed